Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

OBJECTIVES: The primary objective was to determine the response rate in patients with metastatic pancreatic cancer treated in first line with irinotecan/docetaxel combination (Arm A) or with irinotecan/docetaxel/cetuximab combination (Arm B). Secondary endpoints were progression-free survival (PFS),...

Descripción completa

Detalles Bibliográficos
Autores principales: Burtness, Barbara, Powell, Mark, Catalano, Paul, Berlin, Jordan, Liles, Darla K., Chapman, Andrew E., Mitchell, Edith, Benson, Al B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Articles: Gastrointestinal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177955/
https://www.ncbi.nlm.nih.gov/pubmed/24685886
http://dx.doi.org/10.1097/COC.0000000000000068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177955/
https://www.ncbi.nlm.nih.gov/pubmed/24685886
http://dx.doi.org/10.1097/COC.0000000000000068

Ejemplares similares